Medical Animation: Cancer ADC MOA
Created for Exelixis, Inc.
Link copied!
XB002 mechanism of action (MOA) animation title screen. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor. Unlike other tissue factor ADCs, XB002 does not interfere with the normal hemostatic function of tissue factor. © 2023 Exelixis, Inc.
XB002 mechanism of action (MOA) animation. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor. Unlike other tissue factor ADCs, XB002 does not interfere with the normal hemostatic function of tissue factor. © 2023 Exelixis, Inc.
XB002 mechanism of action (MOA) animation. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor. Unlike other tissue factor ADCs, XB002 does not interfere with the normal hemostatic function of tissue factor. © 2023 Exelixis, Inc.
XB002 mechanism of action (MOA) animation. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor. Unlike other tissue factor ADCs, XB002 does not interfere with the normal hemostatic function of tissue factor. © 2023 Exelixis, Inc.
The project
Tissue factor (TF) overexpression and non-hemostatic signaling is seen in many tumors; however, TF-targeting therapies can disrupt the normal hemostatic function of TF, limiting their clinical benefit. We created this medical animation to educate HCPs about the MOA of a novel antibody-drug conjugate (ADC), XB002, which targets TF-expressing tumor cells without disrupting normal TF function. Multiple data sources were used to visualize TF and its binding partners in order to communicate the innovative MOA of XB002. Molecular interactions of TF were shown in an inset overlaying a blood vessel environment, so that they could be easily related to tissue-level events.
Created for
Exelixis, Inc.
